16,463 Shares in CONMED Corporation $CNMD Bought by Oppenheimer Asset Management Inc.

Oppenheimer Asset Management Inc. bought a new position in CONMED Corporation (NYSE:CNMD) during the 2nd quarter, Holdings Channel.com reports. The institutional investor bought 16,463 shares of the company’s stock, valued at approximately $539,000.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Kelleher Financial Advisors bought a new position in shares of CONMED during the third quarter worth about $28,000. Kestra Advisory Services LLC acquired a new stake in shares of CONMED in the 4th quarter worth about $26,000. Aster Capital Management DIFC Ltd lifted its position in CONMED by 409.2% in the 4th quarter. Aster Capital Management DIFC Ltd now owns 723 shares of the company’s stock valued at $29,000 after purchasing an additional 581 shares during the last quarter. Quarry LP boosted its stake in CONMED by 244.8% during the 3rd quarter. Quarry LP now owns 869 shares of the company’s stock valued at $41,000 after purchasing an additional 617 shares during the period. Finally, Rockefeller Capital Management L.P. boosted its stake in CONMED by 48.6% during the 4th quarter. Rockefeller Capital Management L.P. now owns 1,043 shares of the company’s stock valued at $42,000 after purchasing an additional 341 shares during the period.

Wall Street Analyst Weigh In

Several equities research analysts have commented on CNMD shares. JPMorgan Chase & Co. dropped their price target on shares of CONMED from $43.00 to $40.00 and set a “neutral” rating on the stock in a research note on Thursday, April 30th. Wall Street Zen upgraded CONMED from a “hold” rating to a “buy” rating in a research report on Monday, July 20th. Weiss Ratings raised CONMED from a “sell (d)” rating to a “sell (d+)” rating in a report on Wednesday, August 5th. Zacks Research upgraded CONMED from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 11th. Finally, Piper Sandler reaffirmed a “neutral” rating and set a $45.00 target price (up from $39.00) on shares of CONMED in a research note on Thursday, July 30th. Six equities research analysts have rated the stock with a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, CONMED currently has an average rating of “Reduce” and a consensus target price of $41.40.

CONMED Stock Performance

Shares of CNMD opened at $49.08 on Tuesday. The firm has a market capitalization of $1.47 billion, a PE ratio of 26.53, a P/E/G ratio of 2.30 and a beta of 0.88. The company has a quick ratio of 0.69, a current ratio of 1.48 and a debt-to-equity ratio of 0.63. The firm has a 50-day moving average price of $40.50 and a 200 day moving average price of $39.10. CONMED Corporation has a 52-week low of $31.44 and a 52-week high of $56.63.

CONMED (NYSE:CNMD) last released its quarterly earnings results on Wednesday, July 29th. The company reported $1.38 EPS for the quarter, topping analysts’ consensus estimates of $1.11 by $0.27. The company had revenue of $343.49 million for the quarter, compared to the consensus estimate of $337.60 million. CONMED had a net margin of 4.12% and a return on equity of 14.31%. CONMED’s revenue was up .3% on a year-over-year basis. During the same period in the previous year, the firm earned $1.15 EPS. CONMED has set its FY 2026 guidance at 4.480-4.600 EPS. On average, sell-side analysts anticipate that CONMED Corporation will post 4.54 earnings per share for the current fiscal year.

About CONMED

CONMED Corporation (NYSE: CNMD) is a global medical technology company headquartered in Utica, New York. Founded in 1970, CONMED develops, manufactures and markets a broad portfolio of surgical devices and accessories for minimally invasive procedures. The company’s product line supports surgeons and healthcare providers in specialties including orthopedics, general surgery, gastroenterology and gynecology.

CONMED operates two principal segments: Orthopedics, and Visualization & Energy.